Get started
Author

Mahlatse Kgokolo

Observed names: Kgokolo, Mahlatse C.M., M. Kgokolo, MC Kgokolo, Mahlatse C. M. Kgokolo, Mahlatse C.M. Kgokolo, Mahlatse Cordelia Kgokolo, Mahlatse M. C. Kgokolo
ORCID: 0000-0003-0362-1497
Observed ORCID: 0000-0003-0362-1497
OpenAlex ID: A5035973780
AI and precision oncology in clinical cancer genomics: From prevention to targeted cancer therapies-an outcomes based patient care
2022 · Zodwa Dlamini, Amanda Skepu, et al. · Informatics in Medicine Unlocked · 52
PDF
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma
2022 · Nonkululeko Z. Malinga, Shalete C. Siwele, et al. · Translational Oncology · 24
PDF
Clinical Presentations of Severe Cutaneous Drug Reactions in HIV-Infected Africans
2013 · Rannakoe J. Lehloenya, Mahlatse Kgokolo · Dermatologic Clinics · 16
Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients
2022 · Mahlatse C. M. Kgokolo, Katherine Anderson, et al. · Frontiers in Oncology · 13
PDF
Xeroderma pigmentosum in South Africa: Evidence for a prevalent founder effect
2019 · M. Kgokolo, F. Morice‐Picard, et al. · British Journal of Dermatology · 13
PDF
Current and Emerging Insights into the Causes, Immunopathogenesis, and Treatment of Cutaneous Squamous Cell Carcinoma
2025 · Ronald Anderson, Nomzamo M. Mkhize, et al. · Cancers · 10
PDF
Applying Artificial Intelligence Prediction Tools for Advancing Precision Oncology in Immunotherapy: Future Perspectives in Personalized Care
2023 · Botle Precious Damane, Zilungile Lynette Mkhize-Kwitshana, et al. · Springer eBooks · 5
Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma
2024 · Mahlatse C.M. Kgokolo, Nonkululeko Z. Malinga, et al. · Translational Oncology · 4
Future directions in cervical cancer treatment
2024 · Botle Precious Damane, Thanyani Victor Mulaudzi, et al. · Elsevier eBooks · 4
Atypical presentations of mucocutaneous TB in HIV: A case series from South Africa
2025 · Mahlatse Cordelia Kgokolo, Mohlominyane Jeffrey Mokheseng, et al. · Journal of Clinical Tuberculosis and Other Mycobacterial Diseases · 2
Integration of Cyber-Physical Systems in the Advancement of Society 5.0 Healthcare Management
2023 · Botle Precious Damane, Mahlatse Cordelia Kgokolo, et al. · Springer eBooks · 2
Acne vulgaris and variants
2024 · JJ Makhubele, JM Mokheseng, et al. · South African General Practitioner · 1
A Case Report of a Patient With Recalcitrant Pemphigus Vulgaris Treated With Rituximab
2026 · Mahlatse Cordelia Kgokolo, Lesedi Makgwethele Nevondo, et al. · Clinical Case Reports
Patient-Centric Technologies
2025 · Demetra Demetriou, Zodwa Dlamini, et al. · CRC Press eBooks
Contributors
2024 · Shisana Baloyi, Afra Basera, et al. · Elsevier eBooks
1150P Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
2023 · B.L. Rapoport, R. Anderson, et al. · Annals of Oncology
PDF
Biomarkers for disease progression identified in psoriasis patients: A pilot study
2023 · Nomzamo Mkhize, Mahlatse Kgokolo, et al. · JEADV Clinical Practice
PDF
Transforming growth factor-b1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma.
2023 · Bernardo Leon Rapoport, Ronald Anderson, et al. · Journal of Clinical Oncology
84 Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma
2022 · Nonkululeko Z Malinga, Bernardo Rapoport, et al. · Regular and Young Investigator Award Abstracts
PDF
870P Systemic levels of the soluble co-inhibitory and co-stimulatory immune checkpoint molecules in basal cell carcinoma
2022 · B.L. Rapoport, N. Malinga, et al. · Annals of Oncology
Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1, and TIM-3 are markedly increased in basal cell carcinoma.
2022 · Bernardo Leon Rapoport, Nonkululeko Malinga, et al. · Journal of Clinical Oncology
Works count: 22
Citation count: 148
H-index: 6
I10-index: 6
Year
Topic
Type